• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Ziegelmann on Peyronie's disease: “Collagenase remains a very important treatment option”

Video

“Completing those 4 injection cycles is likely to yield the best clinical outcomes for most of our patients,” says Matthew J. Ziegelmann, MD.

In this video, Matthew J. Ziegelmann, MD, discusses the takeaways of the study, “Collagenase clostridium histolyticum treatment for Peyronie’s disease: analysis of outcomes and cumulative benefits after each injection cycle,” presented recently at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting. Ziegelmann is a urologist at the Mayo Clinic, Rochester, Minnesota.

Related Videos
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Gamal M. Ghoniem, MD, FACS, ABU/FPMRS, gives an answer during a video interview
Edward M. Schaeffer, MD, PhD, answers a question during a Zoom video interview
Zhina Sadeghi, MD, answers a question during a video interview
Stephanie Gleicher, MD, answers a question during a Zoom video interview
Human kidney cross section on scientific background | © Crystal light - stock.adobe.com
Mature woman with her doctor | Image Credit: © pucko_ns - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.